Research status of hyperprogressive disease induced by immune checkpoint inhibitors in cancer and its occurrence in gynecologic cancer
10.3760/cma.j.cn114015-20241008-00079
- VernacularTitle:免疫检查点抑制剂致恶性肿瘤超进展的研究现状及其在妇科肿瘤中的发生情况
- Author:
Aihua GUO
1
;
Ciren GUO
1
;
Yang SUN
1
Author Information
1. 福建医科大学肿瘤临床医学院，福建省肿瘤医院妇科，福州 350014
- Publication Type:Journal Article
- Keywords:
Immune checkpoint inhibitors;
Carcinoma;
Uterine neoplasms;
Ovarian neoplasms;
Uterine cervical neoplasms;
Hyperprogression disease
- From:
Adverse Drug Reactions Journal
2025;27(7):428-434
- CountryChina
- Language:Chinese
-
Abstract:
Immune checkpoint inhibitors (ICIs) have made great progress in the field of oncology, becoming one of the indispensable therapeutic approaches. However, the hyperprogressive disease (HPD) following treatment, observed in a few patients, has raised widespread clinical concern due to its association with rapid disease deterioration. Despite the extensive researches on HPD in recent years, its definition, underlying mechanisms, predictive methods, and management strategies remain unclear. The indications of ICIs in gynecologic cancer were approved relatively later, and there were few reports and studies on HPD after immunotherapy. This article reviews the incidence, influencing factors, mechanisms, differentiation from pseudoprogression, prevention and management of HPD caused by ICIs and its occurrence in gynecologic cancer, in order to promote the research on HPD after ICIs treatment in gynecological malignant tumors, and provide reference and help for the safe application of ICIs in gynecological malignant tumors.
